Research Topics
Genomes and GenesSpecies | Douglas McNeelSummaryAffiliation: University of Wisconsin Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic studyDahua Zhang
Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53792, USA
Invest New Drugs 25:49-55. 2007..MEDI-522 is a second generation humanized anti-alphavbeta3 antibody designed for antiangiogenic therapy. The purpose of this study was to examine potential effects of this agent on blood vessels...
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancerDouglas G McNeel
University of Wisconsin Carbone Cancer Center, Madison, 53792, USA
Cancer Immunol Immunother 61:1137-47. 2012..The identification of delayed, prolonged favorable changes in serum PSA suggests that future studies could explore this combination in studies evaluating time to disease progression...- His-tag ELISA for the detection of humoral tumor-specific immunityVivian Goodell
Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109 8050, USA
BMC Immunol 9:23. 2008.... - Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancerDouglas G McNeel
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Department of Biostatistics, University of Wisconsin, Madison, WI, USA
J Clin Oncol 27:4047-54. 2009..We report here the results of a phase I/IIa trial conducted with a DNA vaccine encoding human PAP in patients with stage D0 prostate cancer... - Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvantDouglas G McNeel
Department of Medicine, Section of Medical Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
J Clin Immunol 23:62-72. 2003.... - Prostate cancer immunotherapyDouglas G McNeel
Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Curr Opin Urol 17:175-81. 2007..This article reviews recent published findings in the area of prostate cancer immunotherapies, focusing on both passive and active immunotherapy approaches that have entered clinical trials... - Cellular immunotherapies for prostate cancerDouglas G McNeel
Department of Medicine Medical Oncology, University of Wisconsin Comprehensive Cancer Center, K4 518 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
Biomed Pharmacother 61:315-22. 2007..We review here two cellular immunotherapies furthest in clinical development for prostate cancer, and discuss the potential challenges to the treating oncologist with the possible advent of these new therapies... - Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusionDouglas G McNeel
University of Wisconsin Comprehensive Cancer Center, Madison, 53792, USA
Clin Cancer Res 11:7851-60. 2005..These findings suggest the MEDI-522 could be further investigated as an antiangiogenic agent for the treatment of cancer... - Immune-based therapies for prostate cancerDouglas G McNeel
Department of Medicine, University of Wisconsin Medical School, 600 Highland Avenue, Madison, WI 53792, USA
Immunol Lett 96:3-9. 2005..The findings from current trials, and the likely combination of current immunotherapy approaches with conventional therapies, portends a hopeful future for the treatment of prostate cancer... - A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancerSarah Zlotocha
Genitourinary Oncology Group at University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Clin Genitourin Cancer 4:215-8. 2005 - Immunotherapy for prostate cancer - recent progress in clinical trialsRyan T Kipp
University of Wisconson School of Medicine and Public Health, Madison, WI, USA
Clin Adv Hematol Oncol 5:465-74, 477-9. 2007..The current article reviews recent trials evaluating immune-modulating agents, antigen-specific active immunotherapy, and combination therapies in clinical development for the treatment of prostate cancer... 
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancerSteven Attia
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
Clin Cancer Res 14:2437-43. 2008..Doxercalciferol (1 alpha-hydroxyvitamin D2) had modest activity in phase I/II trials. Preclinical data support combining vitamin D analogues with docetaxel to treat AIPC...- A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumorsGlenn Liu
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Clin Cancer Res 14:2732-9. 2008..The effect of G3139 treatment on Bcl-2 expression in peripheral blood mononuclear cells (PBMC) and paired tumor biopsies was also determined... - GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancerJames E Ward
Internal Medicine Resident University of Wisconsin, Department of Medicine, Madison, WI 53792, USA
Expert Opin Biol Ther 7:1893-902. 2007.... - Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cellsLaura E Johnson
Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
Cancer Immunol Immunother 56:885-95. 2007..Overall, DNA vaccines provide a safe and effective method of generating prostate antigen-specific T cell responses. These findings support the investigation of PAP-specific DNA vaccines in human clinical trials... - Prostate cancer antigens and vaccines, preclinical developmentsDouglas G McNeel
Department of Medicine, University of Wisconsin, K4/518 Clinical Science Center, Madison, WI 53792, USA
Cancer Chemother Biol Response Modif 22:247-61. 2005 - DNA vaccines for the treatment of prostate cancerSheeba Alam
Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA
Expert Rev Vaccines 9:731-45. 2010..This article focuses on DNA vaccines specifically in the context of prostate cancer treatment, focusing on antigens targeted in preclinical models, recent clinical trials and efforts to improve the potency of these vaccines... - DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancerJordan T Becker
Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI 53705, USA
J Immunother 33:639-47. 2010..Moreover, these results suggest that DNA vaccines targeting PAP could potentially be combined in heterologous immunization strategies with other vaccines to further augment PAP-specific T-cell immunity... - HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson
Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
Cancer Immunol Immunother 59:943-53. 2010..In addition, we propose that the epitopes identified here could be used to monitor immune responses in HLA-A2+ patients receiving vaccines targeting PAP to identify potentially therapeutic immune responses... - Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)Laura E Johnson
Department of Medicine, Section of Medical Oncology, University of Wisconsin-Madison, K4/518 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
Vaccine 24:293-303. 2006..These findings support the further clinical evaluation of pTVG-HP in patients with prostate cancer... - Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositisColin J Mooney
Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA
Int J Urol 13:211-7. 2006..Moreover, given this patient's history and the multiple treatment options for prostate cancer, the identification of dermatomyositis in men should prompt an evaluation to exclude a concurrent diagnosis of prostate cancer... - Newer therapies in advanced prostate cancerRobert B Hegeman
Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Clinical Science Center, Madison, WI 53792, USA
Clin Prostate Cancer 3:150-6. 2004..This article reviews some of the newer therapies being developed and evaluated, including the epothilone analogues, human epidermal growth factor receptor pathway inhibitors, angiogenesis inhibitors, and endothelin receptor antagonists... - Humoral immune responses to testis antigens in sera from patients with prostate cancerLuke H Hoeppner
Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
Cancer Immun 6:1. 2006..Each was independently identified from different subjects with prostate cancer. Antigens identified by these studies can be investigated further as potential prostate cancer tumor antigens... - Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligandEdward J Dunphy
Department of Medicine, Section of Medical Oncology, University of Wisconsin, Madison, Wisconsin 53792, USA
J Immunother 28:268-75. 2005..The authors suggest that MAD-CaP-5 could be explored as a novel prostate cancer antigen, and that this approach can be used to identify immunologically recognized proteins following any specific intervention... - Endothelin receptor antagonists in cancer therapyMihailo Lalich
Genitourinary Oncology Research Group, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
Cancer Invest 25:785-94. 2007..Although this class of drugs is promising for targeted anti-cancer therapy, their role in treatment remains to be defined by completion of future clinical trials... - Methods for constructing and evaluating antitumor DNA vaccinesBrian M Olson
Department of Medicine, Section of Medical Oncology, University of Wisconsin Madison, USA
Methods Mol Biol 542:211-43. 2009..By following these protocols, it is possible to construct, purify, deliver, and evaluate the efficacy of antitumor DNA vaccines... - Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancerBrian M Olson
Department of Oncology, University of Wisconsin Madison, Madison, Wisconsin, USA
Prostate 67:1729-39. 2007..In this report, we evaluated whether patients with prostate cancer have pre-existing immune responses specific for the AR as evidence that the AR also might be pursued as an immunological target antigen... - Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitorJason A Dubovsky
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
Prostate 67:1781-90. 2007..We have been seeking to identify immunologically recognized proteins, cancer-testis antigens (CTA) in particular, in patients with prostate cancer that would be rational target antigens... - An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humansYafei Hou
Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, California 94143, USA
J Clin Invest 119:2031-41. 2009..Moreover, SVS2 and semenogelin are among the relevant autoantigens in mice and humans, respectively... - Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responsesMatthew D Morse
Department of Cancer Biology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI 53705, USA
Hum Immunol 71:496-504. 2010..The optimal timing and sequence of androgen deprivation with immune-based therapies awaits future experimental evaluation... - Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigensMary L Disis
Division of Oncology, University of Washington, Seattle, Washington 98195 6527, USA
Immunobiology 207:179-86. 2003..Antibodies directed against rat neu were not elicited with this approach, indicating that the neu specific T cell immune response elicited with plasmid DNA was skewed towards cell-mediated rather than humoral immunity... - Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus
Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
J Clin Oncol 25:675-81. 2007..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy...
Research Grants
- Androgen receptor targeted vaccines for prostate cancerDouglas G McNeel; Fiscal Year: 2010..Finally, this proposal will evaluate these findings in a human clinical trial in patients at high risk for prostate cancer metastatic recurrence. ..
- A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid PaseDouglas McNeel; Fiscal Year: 2006..This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. ..